Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Not Confirmed
Not Confirmed
27-29 January, 2026
Not Confirmed
Not Confirmed
27-28 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
Industry Trade Show
Not Confirmed
27-29 January, 2026
Industry Trade Show
Not Confirmed
27-28 January, 2026
Digital content
NEWS #PharmaBuzz
07 Apr 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/f-star-charts-new-path-splitting-invox-after-2023s-161m-acquisition
06 Jul 2023
// Kyle LaHucik ENDPTS
https://endpts.com/f-star-bags-third-takeda-tie-up-in-a-year-with-multi-specific-antibodies-for-cancer/
08 Mar 2023
// BUSINESSWIRE
07 Mar 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/03/07/2622160/0/en/F-star-Therapeutics-Announces-CFIUS-Clearance-for-Proposed-Acquisition-by-invoX-Pharma.html
07 Mar 2023
// Amber Tong ENDPTS
https://endpts.com/f-stars-sale-to-chinese-buyer-cleared-by-cfius-following-months-of-holdup/
01 Feb 2023
// MARKETWATCH
https://www.marketwatch.com/story/f-star-therapeutics-stock-jumps-on-extension-to-invox-pharma-merger-deadline-271675271722?mod=markets
Drugs in Development
Details:
Under the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing licence to research, develop, and commercialize a bispecific antibody directed towards an undisclosed immuno-oncology target using F-star’s proprietary Fcab™ and mAb2 ™ platforms.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 22, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
InvoX Pharma’s F-star Announces Licence Agreement With Takeda for Second Novel Next-Generation I...
Details : Under the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing licence to research, develop, and commercialize a bispecific antibody directed towards an undisclosed immuno-oncology target using F-star’s proprietary Fcab™ and mAb...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 22, 2023
Details:
FS118 is a dual checkpoint inhibitor targeting PD-L1 and LAG-3. FS118 is designed to provide unique pharmacology, that drives PD-L1 dependent LAG-3 shedding and receptor down-regulation, via bispecific activity, and potentially offering a more durable response in patients.
Lead Product(s): FS118
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Invox Pharma
Deal Size: $161.0 million Upfront Cash: $161.0 million
Deal Type: Acquisition March 08, 2023
Lead Product(s) : FS118
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Invox Pharma
Deal Size : $161.0 million
Deal Type : Acquisition
invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
Details : FS118 is a dual checkpoint inhibitor targeting PD-L1 and LAG-3. FS118 is designed to provide unique pharmacology, that drives PD-L1 dependent LAG-3 shedding and receptor down-regulation, via bispecific activity, and potentially offering a more durable re...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $161.0 million
March 08, 2023
Details:
FS222 targets critical tumoral immune-suppressing pathways via PD-L1 checkpoint blockade and exhibited important costimulatory effect of potent clustering and activation of CD137, which in turn, promotes T cell activation and enhanced cytotoxic T cell responses.
Lead Product(s): FS222
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 06, 2022
Details : FS222 targets critical tumoral immune-suppressing pathways via PD-L1 checkpoint blockade and exhibited important costimulatory effect of potent clustering and activation of CD137, which in turn, promotes T cell activation and enhanced cytotoxic T cell re...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 06, 2022
Details:
FS118 is a first-in-class tetravalent bispecific antibody binding to LAG-3 and PD-L1, resulting in the reversal of immune suppression. FS118 was well tolerated with no treatment-related serious adverse events and no dose-limiting toxicity, up to 20mg/kg.
Lead Product(s): FS118
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 07, 2022
Lead Product(s) : FS118
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FS118 is a first-in-class tetravalent bispecific antibody binding to LAG-3 and PD-L1, resulting in the reversal of immune suppression. FS118 was well tolerated with no treatment-related serious adverse events and no dose-limiting toxicity, up to 20mg/kg.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 07, 2022
Details:
Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing license to research, develop, and commercialize a bispecific antibody against an immuno-oncology target using F-star’s proprietary Fcab™ and mAb2 ™ platforms.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Takeda Pharmaceutical
Deal Size: $41.0 million Upfront Cash: $1.0 million
Deal Type: Licensing Agreement July 20, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : $41.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing license to research, develop, and commercialize a bispecific antibody against an immuno-oncology target using F-star’s proprietary Fcab™ and mAb2 ™ pl...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $1.0 million
July 20, 2022
Details:
F-star’s unique next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharm’s existing capabilities and reinforces its global oncology pipeline including FS118.
Lead Product(s): FS118
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Invox Pharma
Deal Size: $161.0 million Upfront Cash: $161.0 million
Deal Type: Acquisition June 23, 2022
Lead Product(s) : FS118
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Invox Pharma
Deal Size : $161.0 million
Deal Type : Acquisition
Details : F-star’s unique next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharm’s existing capabilities and reinforces its global oncology pipeline including FS118.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $161.0 million
June 23, 2022
Details:
FS222, a CD137/PD-L1 mAb2 bispecific antibody targets PD-L1, the immune checkpoint protein that regulates the balance of activated T cells in the immune system and is overexpressed on many solid tumors.
Lead Product(s): FS222
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 07, 2021
Details : FS222, a CD137/PD-L1 mAb2 bispecific antibody targets PD-L1, the immune checkpoint protein that regulates the balance of activated T cells in the immune system and is overexpressed on many solid tumors.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 07, 2021
Details:
Under the terms of the agreement, F-star will grant Janssen, a exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star’s proprietary Fcab™ and mAb2™ platforms.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Johnson & Johnson Innovative Medicine
Deal Size: $1,367.5 million Upfront Cash: $17.5 million
Deal Type: Licensing Agreement October 20, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : $1,367.5 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, F-star will grant Janssen, a exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star’s proprietary Fcab™ a...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $17.5 million
October 20, 2021
Details:
FS120, a first-in-class OX40 and CD137 tetravalent dual T cell agonist used in patients with advanced malignancies. Safety and PK/PD data trigger initiation of the previously announced FS120 and KEYTRUDA® (pembrolizumab) combination study, scheduled to start in Q3 2022.
Lead Product(s): FS120
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 16, 2021
F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021
Details : FS120, a first-in-class OX40 and CD137 tetravalent dual T cell agonist used in patients with advanced malignancies. Safety and PK/PD data trigger initiation of the previously announced FS120 and KEYTRUDA® (pembrolizumab) combination study, scheduled to...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 16, 2021
Details:
Under the agreement, MSD will supply KEYTRUDA for a combination arm that will be included in the adaptive Phase 1 clinical protocol of FS120, F-star’s first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 and OX40 in patients with advanced cancer.
Lead Product(s): FS120,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 04, 2021
Lead Product(s) : FS120,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, MSD will supply KEYTRUDA for a combination arm that will be included in the adaptive Phase 1 clinical protocol of FS120, F-star’s first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 and OX40 in patients with...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
August 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
